DESCRIPTION: Itromac-200 Capsule contains Itraconazole, a triazole for the prevention and treatment of invasive allergic fungal infections. Triazole antifungal agents that inhibit cytochrome P-450-dependent enzymes result in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
DOSAGE FORM: Capsules
ROUTE OF ADMINISTRATION: Oral
COMPOSITION: Each hard gelatin capsule contains
|
Itraconazole Pellets |
||
|
Eq. to Itraconazole |
B.P. |
200 mg |
|
Excipients |
q.s. |
|
|
Titanium Dioxide I.P. used in pellets |
||
|
Approved colours are used in the empty capsule shell. |
MECHANISM OF ACTION: Itraconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.
INDICATIONS: For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
DOSAGE: As directed by the physician.
SIDE EFFECTS: Headache, Dizziness, Nausea, Vomiting, Upset Stomach, Constipation and Muscle aches.
CONTRA-INDICATIONS: Contraindicated in patients who have shown hypersensitivity to Itraconazole or the excipients.
STORAGE: Store in a cool and dry place. Protect from light.
PRESENTATION: 10x1x10 Capsules in a cardboard carton.
BARCODE: (01)08906044108820 (01)18906044108827 (01)28906044108824